Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers

Exclusion Criteria

• - Participation in another clinical study with a study drug within 5 half-lives of that study drug or within 3 months prior to screening, whichever is longer
• - Donation of blood or plasma within 2 months prior to screening and until after the final follow-up visit
• - Poor venous access
• - History of severe allergy/hypersensitivity reactions or history of hypersensitivity to immunisations, immunoglobulins or biologics
• - Prescence of any clinically significant illness, such as cardiovascular, neurological, pulmonary, hepatic, renal, metabolic, gastro-intestinal, urologic, immunologic or endocrine disease or disorder
• - History of cancer within 5 years of screening
• - History of drug abuse
• - Use of prescriptions or non-prescription medicines within 7 days or 5 half-lives, whichever is longer, prior to administration of study treatments
• - Any clinical abnormality on complete physical examination, vitals signs, ECG or clinical laboratory test results at screening or between screening and randomisation